Genedata Highlights Combination Screening and Surface Plasmon Resonance at SLAS 2015
News Feb 04, 2015
Genedata has announced its Combination Screening Colloquium at the 4th Annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in Washington, DC (February 8). Genedata will also offer SLAS tutorials on combination screening and surface plasmon resonance (SPR) at the conference. Currently, the majority of leading global pharmaceutical companies use Genedata Screener® as their screening platform for the analysis and management of all plate-based screening data with applications in High Throughput Screening, High Content Screening, Label-free Screening, Ion Channel Screening and Cross-assay Profiling. Live demonstrations of the Genedata Screener platform will be conducted during SLAS 2015 at the Walter E. Washington Convention Center (February 7 - 11; Booth #1010).
Combination Screening Colloquium
Compound Combination Screening is rapidly gaining ground as a new lead-finding technique for oncology, infectious diseases, and drug repurposing. These experiments have made significant progress in the areas of automation and throughput, enabled by technological advances in nanoliter liquid handling and flexible plate preparation, which fuel standardization and automation of data analysis as well. Genedata Screener for Combination Screening supports the analysis of high-throughput compound combination experiments from raw data to obtain synergy scores and combination indices. At the Genedata SLAS Combination Screening Colloquium, some of the industry's most experienced combination screening scientists from around the world together with Genedata computational experts will discuss current methods and challenges for analyzing combination screens. Using case studies, the Colloquium will examine best analysis practices, and automation and standardization options for quickly obtaining more comprehensive and significant results from those experiments.
"Over the years, we have collaborated with leading researchers in the field of combination screening," noted Dr. Othmar Pfannes, CEO of Genedata. "And, we want to share our learnings to help a broader group of researchers address and overcome the challenges commonly experienced in compound combination screening. Our SLAS Combination Screening Colloquium will give the scientific community a forum in which they can exchange ideas, discuss best practices, and define areas of improvement for data analysis. Such exchange with the scientific community enables us to continually incorporate best-practices and learnings from the forefront of screening science into our software systems, which in turn helps researchers to directly apply these learnings in their daily drug discovery efforts."
Genedata Screener Tutorial Sessions
Used as a platform for all plate-based screening, Genedata Screener supports a wide range of related applications and technologies. Genedata Screener SLAS tutorial sessions will showcase some of these applications.
In addition to the Colloquium on February 8, the Genedata Screener for Combination Screening tutorial (Feb. 9) will focus on how data analysis workflows can be standardized for efficiency yet customized to provide additional or modified algorithmic approaches. The Genedata Screener for SPR session (Feb. 10) will demonstrate a vendor-agnostic, single data analysis solution for all SPR/biosensor experiments. Automating all data pre-processing, the solution offers data visualization and analysis optimization on-the-fly, which enables users to focus on result generation and interpretation. Tutorials will examine challenges associated with a heterogeneous data analysis landscape and show the benefits of a common data analysis infrastructure.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE